Individual risk assessment in bladder cancer patients based on a multi-marker panel

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 1, 2013, Pages 49-56

  Todenhöfer, Tilman ^a   Hennenlotter, Jörg ^a   Aufderklamm, Stefan ^a   Kühs, Ursula ^a   Gakis, Georgios ^a   Germann, Miriam ^a   Stenzl, Arnulf ^a   Schwentner, Christian ^a,b  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Bladder cancer; Cystoscopy, risk stratification, cytology; Fluorescence in situ hybridization (FISH); Immunocytology (uCyt+); Nuclear matrix protein 22 (NMP22)

Indexed keywords

NUCLEAR MATRIX PROTEIN 22;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CANCER RISK; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; CYSTOSCOPY; CYTOLOGY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FALSE NEGATIVE RESULT; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOCYTOLOGY; INTERMETHOD COMPARISON; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TRANSURETHRAL RESECTION; URINE CYTOLOGY;

ADULT; AGED; AGED, 80 AND OVER; CYSTECTOMY; CYSTOSCOPY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FALSE NEGATIVE REACTIONS; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NUCLEAR PROTEINS; ODDS RATIO; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84872302091     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1297-9     Document Type: Article

References (28)

1. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J, Roupret M (2011) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol. doi: 10.1016/j.eururo.2011.03.017
2. Bubendorf L (2011) Multiprobe fluorescence in situ hybridization (UroVysion) for the detection of urothelial carcinoma - FISHing for the right catch. Acta Cytol 55(2):113-119. doi: 10.1159/000323652
3. Bubendorf L, Grilli B, Sauter G, Mihatsch MJ, Gasser TC, Dalquen P (2001) Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol 116(1):79-86. doi: 10.1309/K5P2-4Y8B-7L5A-FAA9
4. Budman LI, Kassouf W, Steinberg JR (2008) Biomarkers for detection and surveillance of bladder cancer. Can Urol Assoc J 2(3):212-221
5. Fradet Y, Grossman HB, Gomella L, Lerner S, Cookson M, Albala D, Droller MJ (2007) A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol 178(1):68-73 (discussion 73). doi: 10.1016/j.juro.2007.03.028
6. Greene KL, Berry A, Konety BR (2006) Diagnostic utility of the ImmunoCyt/uCyt+ test in bladder cancer. Rev Urol 8(4):190-197
7. Grossman HB, Soloway M, Messing E, Katz G, Stein B, Kassabian V, Shen Y (2006) Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 295(3):299-305. doi: 10.1001/jama.295.3.299
8. Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, Wolf JS Jr, Schellhammer PF (2007) Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 178(6):2314-2330. doi: 10.1016/j.juro.2007.09.003
9. Hennenlotter J, Huber S, Todenhofer T, Kuehs U, Schilling D, Aufderklamm S, Gakis G, Schwentner C, Stenzl A (2011) Point-of-care tests for bladder cancer: the influencing role of hematuria. Adv Urol 2011:937561. doi: 10.1155/2011/937561
10. Huber S, Schwentner C, Taeger D, Pesch B, Nasterlack M, Leng G, Mayer T, Gawrych K, Bonberg N, Pelster M, Johnen G, Bontrup H, Wellhausser H, Bierfreund HG, Wiens C, Bayer C, Eberle F, Scheuermann B, Kluckert M, Feil G, Bruning T, Stenzl A (2012) Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study. BJU Int. doi: 10.1111/j.1464-410X.2011.10883.x
11. Karakiewicz PI, Benayoun S, Zippe C, Ludecke G, Boman H, Sanchez-Carbayo M, Casella R, Mian C, Friedrich MG, Eissa S, Akaza H, Huland H, Hedelin H, Rupesh R, Miyanaga N, Sagalowsky AI, Marberger MJ, Shariat SF (2006) Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. BJU Int 97(5):997-1001. doi: 10.1111/j.1464-410X.2006.06036.x
12. Kausch I, Sommerauer M, Montorsi F, Stenzl A, Jacqmin D, Jichlinski P, Jocham D, Ziegler A, Vonthein R (2010) Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. Eur Urol 57(4):595-606. doi: 10.1016/j.eururo.2009.11. 041
13. Kehinde EO, Al-Mulla F, Kapila K, Anim JT (2011) Comparison of the sensitivity and specificity of urine cytology, urinary nuclear matrix protein-22 and multitarget fluorescence in situ hybridization assay in the detection of bladder cancer. Scand J Urol Nephrol 45(2):113-121. doi: 10.3109/00365599.2010. 533694
14. Kipp BR, Tyner HL, Campion MB, Voss JS, Karnes RJ, Sebo TJ, Halling KC, Zhang J (2008) Chromosomal alterations detected by fluorescence in situ hybridization in urothelial carcinoma and rarer histologic variants of bladder cancer. Am J Clin Pathol 130(4):552-559. doi: 10.1309/DFJUHY3WPC9GUU2W
15. Mian C, Pycha A, Wiener H, Haitel A, Lodde M, Marberger M (1999) Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract. J Urol 161(5):1486-1489
16. Papanicolaou GN, Marshall VF (1945) Urine sediment smears as a diagnostic procedure in cancers of the urinary tract. Science 101(2629):519-520. doi: 10.1126/science.101.2629.519
17. Riesz P, Lotz G, Paska C, Szendroi A, Majoros A, Nemeth Z, Torzsok P, Szarvas T, Kovalszky I, Schaff Z, Romics I, Kiss A (2007) Detection of bladder cancer from the urine using fluorescence in situ hybridization technique. Pathol Oncol Res 13(3):187-194
18. Sarosdy MF, Kahn PR, Ziffer MD, Love WR, Barkin J, Abara EO, Jansz K, Bridge JA, Johansson SL, Persons DL, Gibson JS (2006) Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria. J Urol 176(1):44-47. doi: 10.1016/S0022-5347(06)00576-3
19. Shariat SF, Casella R, Wians FH, Jr., Ashfaq R, Balko J, Sulser T, Gasser TC, Sagalowsky AI (2004) Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology. Eur Urol 45(3):304-313 (author reply 313). doi: 10.1016/j.eururo.2003.10.020
20. Shariat SF, Marberger MJ, Lotan Y, Sanchez-Carbayo M, Zippe C, Ludecke G, Boman H, Sawczuk I, Friedrich MG, Casella R, Mian C, Eissa S, Akaza H, Serretta V, Huland H, Hedelin H, Raina R, Miyanaga N, Sagalowsky AI, Roehrborn CG, Karakiewicz PI (2006) Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer. J Urol 176(3):919-926 (discussion 926). doi: 10.1016/j.juro.2006.04.017
21. Shariat SF, Karam JA, Lotan Y, Karakiewizc PI (2008) Critical evaluation of urinary markers for bladder cancer detection and monitoring. Rev Urol 10(2):120-135
22. Sharma S, Zippe CD, Pandrangi L, Nelson D, Agarwal A (1999) Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol 162(1):53-57
23. Stenzl A, Penkoff H, Dajc-Sommerer E, Zumbraegel A, Hoeltl L, Scholz M, Riedl C, Bugelnig J, Hobisch A, Burger M, Mikuz G, Pichlmeier U (2010) Detection and clinical outcome of urinary bladder cancer with 5-aminolevulinic acid-induced fluorescence cystoscopy: a multicenter randomized, double-blind, placebo-controlled trial. Cancer. doi: 10.1002/cncr.25523
24. Todenhofer T, Hennenlotter J, Tews V, Gakis G, Aufderklamm S, Kuehs U, Stenzl A, Schwentner C (2011) Impact of different grades of microscopic hematuria on the performance of urine-based markers for the detection of urothelial carcinoma. Urol Oncol. doi: 10.1016/j.urolonc.2011.10.011
25. Todenhofer T, Hennenlotter J, Kuhs U, Tews V, Gakis G, Aufderklamm S, Stenzl A, Schwentner C (2012a) Influence of urinary tract instrumentation and inflammation on the performance of urine markers for the detection of bladder cancer. Urology 79(3):620-625. doi: 10.1016/j.urology.2011.10.067
26. Todenhöfer T, Hennenlotter J, Witstruk M, Gakis G, Aufderklamm S, Kuehs U, Stenzl A, Schwentner C (2012b) Influence of renal excretory function on the performance of urine based markers to detect bladder cancer. J Urol. doi: 10.1016/j.juro.2011.09.023
27. Tritschler S, Scharf S, Karl A, Tilki D, Knuechel R, Hartmann A, Stief CG, Zaak D (2007) Validation of the diagnostic value of NMP22 BladderChek test as a marker for bladder cancer by photodynamic diagnosis. Eur Urol 51(2):403-407 (discussion 407-408). doi: 10.1016/j.eururo.2006.08.001
28. Yoder BJ, Skacel M, Hedgepeth R, Babineau D, Ulchaker JC, Liou LS, Brainard JA, Biscotti CV, Jones JS, Tubbs RR (2007) Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol 127(2):295-301. doi: 10.1309/ADJL7E810U1H42BJ